Drugs / AK154
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06913218 | Jul 2025 → Feb 2028 expected | pancreatic ductal adenocarcinoma | Akeso | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06913218 ↗ |
| Modality | Messenger RNA (mRNA) | “AK154 is neotigeon personalized mRNA vaccine” NCT06913218 ↗ |